标题
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 10, Pages 1441-1448
出版商
Informa Healthcare
发表日期
2014-08-28
DOI
10.1517/13543784.2014.954034
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
- (2014) A. Michael Lincoff et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
- (2013) J R Colca et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Harnessing the benefits of PPARβ/δ agonists
- (2013) Louise S. Mackenzie et al. LIFE SCIENCES
- A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use
- (2013) Sihao Liu et al. NATURE
- The role of hepatokines in metabolism
- (2013) Norbert Stefan et al. Nature Reviews Endocrinology
- Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
- (2012) Ying Chen et al. DIABETES
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study
- (2012) Michel Tiv et al. PLoS One
- Protection from liver fibrosis by a peroxisome proliferator-activated receptor agonist
- (2012) K. Iwaisako et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Thiazolidinediones and PPARγ agonists: time for a reassessment
- (2012) Bertrand Cariou et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
- (2011) E. Boettcher et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Peroxisome Proliferator–Activated Receptor-α Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice
- (2011) Fanny Lalloyer et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Roles of PPARs in NAFLD: Potential therapeutic targets
- (2011) Anne Tailleux et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Cellular and molecular mechanisms of metformin: an overview
- (2011) Benoit Viollet et al. CLINICAL SCIENCE
- Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study
- (2011) R.-D. Ting et al. DIABETES CARE
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- Do fibrates truly preserve kidney function?
- (2011) Suneel M. Udani et al. Nature Reviews Endocrinology
- Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
- (2011) Briohny W. Smith et al. Nature Reviews Endocrinology
- The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact
- (2011) Esther Phielix et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors
- (2010) Fanny Lalloyer et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
- (2010) Renata Belfort et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A position statement on NAFLD/NASH based on the EASL 2009 special conference
- (2010) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Roles of liver innate immune cells in nonalcoholic fatty liver disease
- (2010) Yu-Tao Zhan WORLD JOURNAL OF GASTROENTEROLOGY
- Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice
- (2008) Catherine Postic et al. JOURNAL OF CLINICAL INVESTIGATION
- Fibrates and future PPARα agonists in the treatment of cardiovascular disease
- (2008) Bart Staels et al. Nature clinical practice. Cardiovascular medicine
- Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses
- (2007) Leena Juurinen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started